Key result
Advances in molecular imaging modalities, including MRI, CT, PET, and SPECT, have improved the understanding of thrombotic disease and hold promise for earlier diagnosis and individualized therapy.
Why the study?
Thrombosis contributes to one in four deaths worldwide, and reliable, rapid diagnosis is needed to enable immediate therapy and reduce mortality and morbidity.
Molecular imaging techniques offer promising advancements for the rapid and reliable diagnosis of arterial and venous thrombosis, potentially improving patient outcomes.
May enable earlier thrombosis detection; leaves open prospective validation before clinical use.
Thrombosis contributes to one in four deaths worldwide and is the cause of a large proportion of mortality and morbidity. A reliable and rapid diagnosis of thrombosis will allow for immediate therapy, thereby providing significant benefits to patients. Molecular imaging is a fast-growing and captivating area of research, in both preclinical and clinical applications. Major advances have been achieved by improvements in three central areas of molecular imaging: 1) Better markers for diseases, with increased sensitivity and selectivity; 2) Optimised contrast agents with improved signal to noise ratio; 3) Progress in scanner technologies with higher sensitivity and resolution. Clinically available imaging modalities used for molecular imaging include, magnetic resonance imaging (MRI), X-ray computed tomography (CT), ultrasound, as well as nuclear imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT). In the preclinical imaging field, optical (fluorescence and bioluminescent) molecular imaging has provided new mechanistic insights in the pathology of thrombembolic diseases. Overall, the advances in molecular imaging, driven by the collaboration of various scientific disciplines, have substantially contributed to an improved understanding of thrombotic disease, and raises the exciting prospect of earlier diagnosis and individualised therapy for cardiovascular diseases. As such, these advances hold significant promise to be translated to clinical practice and ultimately to reduce mortality and morbidity in patients with thromboembolic diseases.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) conducted a review in Arterial and Venous Thrombosis. Molecular imaging was evaluated. Advances in molecular imaging modalities, including MRI, CT, PET, and SPECT, have improved the understanding of thrombotic disease and hold promise for earlier diagnosis and individualized therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: